Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch?
31.01.26 12:45 Uhr
Werbung
Werte in diesem Artikel
Indizes
PKT PKT
1.723,0 PKT 3,1 PKT 0,18%
1.380,2 PKT 3,4 PKT 0,24%
2.699,0 PKT 11,6 PKT 0,43%
5.123,8 PKT 39,7 PKT 0,78%
Last year wasn't great for Novo Nordisk (NYSE: NVO). One of the biggest challenges it faced was losing ground in the all-important weight loss market to its biggest competitor, Eli Lilly.However, Novo Nordisk has a plan to get things back on track, and the company's oral Wegovy is part of that strategy. In December, Novo Nordisk earned approval for the oral version of its famous medicine, which it launched earlier this month. And so far, things are looking very encouraging for this new product.Should investors buy Novo Nordisk's shares given these developments?Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Quelle: MotleyFool
